Current Research Trials (October 2014)


Randomised trial testing dose escalated intensity modulated radiotherapy for women treated by breast conservation surgery and appropriate systemic therapy for early breast cancer.


Duration of Trastuzumab with Chemotherapy in Women with Early Breast Cancer.  Randomising between 6 months and 12 months of adjuvant Herceptin.


1st line chemotherapy for metastatic, triple negative breast cancer.  Weekly chemotherapy treatment.


Hormone receptor positive, HER-2 negative metastatic breast cancer.  Randomising between 4 treatment arms – all patients receive Fulvestrant, an endocrine treatment administered monthly by intramuscular injection, either as a single agent treatment or in combination with an mTOR inhibitor (Everolimus or a newer agent AZD2014) administered as tablets.


An interview and questionnaire study looking at the treatment decision making process in patients with metastatic cancer.


Comparing Dalteparin (low molecular weight heparin) given as daily injections with Rivaroxaban (a direct Factor Xa inhibitor) given as tablets to patients with active cancer who are diagnosed with a deep vein thrombosis or pulmonary embolism.